Atrial fibrillation;Vorhofflimmern

Internist

Volumn 47, Issue 10, 2006, Pages 990-1000

  Hennersdorf, M G ^a   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

ACE inhibitors; Antiarrhythmic therapy; AT antagonists; Atrial fibrillation; Cardioversion

Indexed keywords

AJMALINE; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; CLOPIDOGREL; COUMARIN; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; HEPARIN; IBUTILIDE; IRBESARTAN; LOSARTAN; PRAJMALINE; PROPAFENONE; QUINIDINE; SOTALOL; VALSARTAN; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; CARDIOVERSION; COMORBIDITY; DRUG EFFICACY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LIVER TOXICITY; MORBIDITY; PREVALENCE; RISK FACTOR; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION;

EID: 33749533259     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1693-9     Document Type: Article

References (31)

1. Albers GW, Diener HC, Frison L et al. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293: 690-698
2. Alboni P, Botto GL, Baldi N et al. (2004) Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351: 2384-2391
3. Boldt A, Scholl A, Garbade J et al. (2006) ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101: 261-267
4. Budeus M, Hennersdorf M, Dierkes S et al. (2003) Effects of right coronary artery PTCA on variables of P-wave signal averaged electrocardiogram. Ann Noninvasive Electrocardiol 8: 150-156
5. Diener HC (2006) Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 21: 279-293
6. Ellenbogen KA, Stambler BS, Wood MA (1996) Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28: 130-136
7. Engelmann MD, Svendsen JH (2005) Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26: 2083-2092
8. Fetsch T, Bauer P, Engberding R et al. (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25: 1385-1394
9. Fogari R, Mugellini A, Destro M et al. (2006) Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 47: 46-50
10. Goette A, Arndt M, Rocken C et al. (2000) Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101: 2678-2681
11. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A et al. (2006) Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 97: 659-661
12. Hennersdorf MG, Perings SM, Zuhlke C et al. (2002) Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Intensive Care Med 28: 925-929
13. Hennersdorf MG, Schannwell CM, Schwartzkopff B, Strauer BE (2003) Hypertrophieregression als Therapieoption bei Hochdruckherz. Herz 28: 764-778
14. Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation - pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356: 1789-1794
15. Kalus JS, Coleman CI, White CM (2006) The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 46: 21-28
16. Kumagai K, Nakashima H, Urata H et al. (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41: 2197-2204
17. Levy S, Camm AJ, Saksena S et al. (2003) International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 5: 119-122
18. Madrid AH, Bueno MG, Rebollo JM et al. (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106: 331-336
19. Maggioni AP, Latini R, Carson PE et al. (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149: 548-557
20. Nakashima H, Kumagai K, Urata H et al. (2000) Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101: 2612-2617
21. Nieuwlaat R, Capucci A, Camm AJ et al. (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26: 2422-2434
22. Pedersen OD, Bagger H, Kober L et al. (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100: 376-380
23. Roy D, Talajic M, Dorian P et al. (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342: 913-920
24. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE (2000) Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 36: 220-225
25. Stellbrink C, Nixdorff U, Hofmann T et al. (2004) Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109: 997-1003
26. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrilation. N Engl J Med 347: 1825-1833
27. Thrall G, Lane D, Carroll D, Lip GY (2006) Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119: 448-419
28. Touboul P, Brugada J, Capucci A et al. (2003) Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24: 1481-1487
29. van Gelder IC, Hangens VE, Bosker HA et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834-1840
30. Wachtell K, Hornestam B, Lehto M et al. (2005) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45: 705-711
31. Wazni O, Martin DO, Marrouche NF et al. (2005) C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 91: 1303-1305